Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
1
Biosurfactant composition produced by a new Bacillus licheniformis strain,
uses and products thereof
Field of the invention
The present disclosure concerns a new Bacillus licheniformis strain, a
biosurfactant composition produced by such a bacterial strain, as well as uses
of
such a biosurfactant composition and products containing such a biosurfactant
composition in association with biocides in industrial and medical field.
Background of the invention
A biofilm is a community of microorganisms attached to a surface,
surrounded by an extracellular polymeric substance (EPS) made of
polysaccharides, DNA and proteins, able to protect microbes from environmental
assaults. Bacterial attachment to surfaces and consequent biofilm formation
are
known phenomena in diverse environments such as medical and food industry
devices.
Bacteria growing as a biofilm remain a significant challenge as they tend
to be more tolerant to antimicrobial treatments.
Biofilms are an important cause of infections associated with biomaterials
and urinary tract infections (UTIs) and are an important cause of nosocomial
infections with significant morbidity, mortality and additional hospital
costs.
Intact host defence systems usually eliminate transient bacterial
contamination or colonization, but the presence of foreign bodies, such as
catheters and implants, lowers the threshold of bacterial sustainable
infection and
generates local immunosuppression allowing biofilm formation on foreign
surfaces in the human body, that tends to be recalcitrant to standard
antimicrobial
treatment. The biofilm formation can, in fact, immediately start once a
biomedical
device has been placed in its body niche. As frequent replacement of the
prosthesis due to bacterial infection is uncomfortable, costly, time consuming
and
may lead to damage of the cellular tissue of patients, alternative approaches
to
catheter infection treatments must be found. Approximately 80% of nosocomial
UTIs are associated with the use of indwelling urinary catheters and UTIs are
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
2
responsible for 40-60% of all hospital-acquired infections. Bacteria found
adhering to the intraluminal surfaces of catheters are the principal source
and
cause of bloodstream infections. Approximately five million central venous
catheters are inserted per year, and of these 3-8% lead to bloodstream
infection.
The attributable mortality of these bloodstream infections is 12-25%. In
contrast,
the mortality rate of catheter-associated UTI is less than 5%. Escherichia
coli is
one of the most prevalent pathogens in UTIs such as prostatitis in adult men
and
cystitis in women.
Biofilm infection and its correlated diseases can be limited by preventing
microbial adhesion to tissues and/or medical device surfaces but also an
effective
therapy to eliminate an existing biofilm is desirable.
Biosurfactants, amphiphilic metabolites produced by a wide group of
bacteria from various biochemical building blocks, can be a useful approach to
challenge bacteria growing as a biofilm. Microbial biosurfactants include a
wide
variety of surface-active compounds such as glycolipids, lipopeptides,
polysaccharide-protein complexes, phospholipids, fatty acids and neutral
lipids.
Among the many classes of biosurfactants, lipopeptides (surfactin, iturin and
fengycin classes) are particularly interesting because of high surface
activity and
antibiotic potential.
surfactin is a mixture of cyclic lipopeptides built from variants of a
heptapeptide and a (3-hydroxyl fatty acid with chain length of 13-15 carbon
atoms.
It is produced by various Bacillus strains. A lactone bridge between the f3-
hydroxyl function of the acid and the carboxy-terminal function of the peptide
confers a cyclic structure to this molecule. A natural diversity occurs,
giving rise
to homologues differing from each other by the acyl chain length (13 to 15
atoms
of carbon) and further isoforms are characterized by differences in the amino
acid
sequence.
fengycin family consists of a (3-hydroxy fatty acid connected to the N-
terminus of a decapeptide, including four D-amino acid residues and the rare
amino acid L-ornithine. The C-terminal residue of the peptide moiety is linked
to
the tyrosine residue at position 3, forming the branching point of the
acylpeptide
and the eight-membered cyclic lactone. fengycin consists of two isoforms,
fengycin A and B, which differ in their amino acid sequences. fengycin A
presents Ala at position 6, fengycin B presents Val at the same position. The
length of the (3-hydroxy fatty acid tail is variable (from C14 to C18) and
links the
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
3
amino group of its N-terminal amino acid Glu. Different homologous compounds
for each lipopeptide family are thus usually coproduced by the same bacterial
strain.
Biosurfactants have advantages over their synthetic chemical counterparts
because of their biodegradability and reduced toxicity, availability from
cheap raw
materials, biocompatibility and the effectiveness at extreme temperature, pH
and
salinity. Biosurfactants have found possible applications in biomedical
fields.
Organisms within a biofilm are difficult to eradicate by conventional
antimicrobial therapy and can cause indolent infections. Resistance of
bacterial
infections to antibiotics is increasing worldwide and some older antimicrobial
agents are no longer recommended because of high levels of resistance.
Antibiotics and biocides may kill the free-living microorganisms
(planktonic), but are not fully effective in killing organisms in a biofilm,
leaving
viable cells on surfaces. EPS confers protection from cellular immunity, by
preventing phagocytosis, and from antibiotics. In addition, biofilms show
increased resistance to antibiotics by decreasing antibiotic penetration
through
EPS, upregulating multi-drug efflux pump expression and expressing periplasmic
glucans that directly bind to and sequester antibiotics.
Bacteria in deep biofilm layers can be less metabolically active, compared
with their planktonic counterparts and, thus, appear to be more resistant to
antibiotics. Bacteria living in a biofilm can create self-generated diversity
that
insures the survival of microorganisms sharing enzymes and proteins produced
by
other community members.
Several attempts have been made to avoid biofilm formation by
incorporation of biocides into surface materials or by coating surfaces with
biocides, especially in the medical field. It has been suggested that
strategies for
antimicrobial use in UTIs should be based on more potent antimicrobial agents,
not necessarily broader-spectrum agents, and appropriate dosage and duration
of
antibiotic treatment.
Summary of the invention
The need is therefore felt for the identification of new compositions
effective against different biofilm and planktonic bacterial strains, in order
to
prevent microbial colonization and growth, on abiotic and biotic surfaces.
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
4
The object of this disclosure is providing such compositions.
According to the invention, the above object is achieved thanks to the
subject matter recalled specifically in the ensuing claims, which are
understood as
forming an integral part of this disclosure.
An embodiment of the present disclosure provides a new Bacillus
licheniformis strain named V9T14 (deposited by Marcopolo Engineering S.p.A.
with the Deutsche Sammlung von Mikroorganismen and Zellkulturen on January
10, 2008 with accession number DMS 21038) and a new biosurfactant
composition effective against different biofilm and planktonic bacterial
strains
produced by such new Bacillus licheniformis strain.
A further embodiment provides the use of such a biosurfactant
composition, optionally in combination with at least one biocide, to prevent
the
colonization and/or biofilm formation from bacteria on abiotic surfaces, like
medical device surfaces, hospital surfaces and/or food industry surfaces.
A further embodiment of the present disclosure concerns the biosurfactant
composition, optionally in association with at least one biocide, for the
prevention
and/or treatment of an infection caused by bacteria able to grow
planktonically
and/or as a biofilm. The biosurfactant composition, optionally in association
with
at least one biocide, is suitable for topical administration to a patient, in
particular
is suitable for skin and/or mucosa application.
A further embodiment provides a product containing the biosurfactant
composition and at least one antibiotic as a combined preparation for
simultaneous, separate or sequential use for the prevention and/or treatment
of an
infection caused by bacteria able to grow planktonically and/or as a biofilm,
preferably on biotic surfaces.
In a still further embodiment, the present disclosure concerns a device,
preferably biomedical device to be inserted and/or implanted in a human or
animal body, comprising on its surfaces the biosurfactant composition,
optionally
in combination with at least one biocide. Devices of this type can be
catheters,
implants, prostheses, etc.
Brief description of the drawings
The invention will now be described, by way of example only, with
reference to the enclosed figures of drawing, wherein:
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
- Figure 1. Growth and culture supernatant oil displacement diameter of B.
licheniformis V9T14. The strain was grown in Luria Bertani broth (LB) at 28 C.
Oil spreading diameters were measured after removal of cells by
centrifugation.
Values are average for three cultures.
5 - Figure 2. A plot of surface tension as a function of concentration of
V9T14 biosurfactant after extraction. Standard deviation was ranging between
0.3 mN/m,
- Figure 3a and 3b. Surface tension of extracted V9T14 biosurfactant as a
function of NaCl concentration (3a) and pH (3b). For NaCl dependence (3a),
biosurfactant was dissolved in water, and the final pH was adjusted to 7.0
with IN
NaOH. Different concentrations of halogen were dissolved in the solution. CMC
was calculated as the intercept of two straight lines extrapolated from the
concentration-dependent and concentration-independent sections of a curve
plotted between biosurfactant concentration and surface tension values. For pH
dependence (3b), pH was adjusted with 3N NaOH or 3N HC1 and surface tension
was measured. Surface tension of distilled water at pH 7.0 was 71.2 mN/m.
Surface tension was measured in triplicate by a du Nouy ring tensiometer.
- Figure 4a and 4b. The adhesion of E. coli CFT073 biofilm in the
presence of different concentrations of V9T14 biosurfactant by precoating the
Calgary Biofilm Device (CBD) pegs (4a) or by adding different amounts of
V9T14 to each well of a 96-well plate (4b). * P<0.01
- Figure 5. Influence of V9T14 biosurfactant on planktonic E. coli
CFT073 growth.
- Figure 6. Effect of V9T14 biosurfactant against microbial adhesion of
different strains.
- Figure 7a and 7b. Confocal Laser Scanning Microscopy analysis of
Acridine Orange stained E. coli CFT073 biofilm formation growth in the
presence of V9T14. Untreated control (7a) and inhibition of bacterial adhesion
by
V9T14 (7b) are shown. Bacteria were incubated in the Calgary Biofilm Device in
LB broth with or without the biosurfactant and analysed for biofilm formation
after 24 h using CLSM. Concentration of V9T14 biosurfactant was 10 g/well.
- Figure 8. Amylase and cellulase production at 28 C after 24 and 48 h.
Bacteria were grown on M9 agar minimal medium supplemented with 0.5%
starch or carboxymethylcellulose. Area of the clear halo was measured after
detection with Lugol solution or Congo red solution respectively.
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
6
- Figure 9. FT-IR spectrum of V9T14.
- Figure 10. ESI-MS positive full scan spectrum of crude lipopeptides
extract.
- Figure 11. ESI-MS positive full scan spectrum of crude lipopeptides
extract, surfactin family.
- Figure 12. ESI-MS/MS spectrum of the precursor ion m/z 1058.7.
- Figure 13. ESI-MS/MS spectrum of the precursor ion m/z 1044.8.
- Figure 14. ESI-MS/MS spectrum of the precursor ion m/z 1030.9.
- Figure 15. ESI-MS positive full scan spectrum of crude lipopeptides
extract, fengycin family.
- Figure 16. ESI-MS/MS spectrum of the precursor ion m/z 1478.4.
- Figure 17. ESI-MS/MS spectrum of the precursor ion m/z 1506.4.
- Figure 18. HPLC-MS negative scan spectrum of biosurfactant extract
V9T14.
- Figure 19. HPLC-MS total ion chromatograms. Biosurfactant extract
V9T14 fengycin and surfactin homologues are evidenced.
- Figure 20. Planktonic and biofilm susceptibility of E. coli CFT073 to
V9T14 biosurfactant alone. Biofilm was grown into the Calgary Biofilm Device
for 24 h at 37 C under shearing forces, then was exposed to different
concentrations of biosurfactant for 24 h.
- Figure 21a, 21b and 21c. Survival of planktonic and adherent microbial
cells at the MIC value of antibiotics against E. coli CFT073 without the
presence
of V9T14 biosurfactant. Antibiotics tested were ceftriaxone (CTR at 1 g/mL),
ciprofloxacin (CIPRO at 1 g/mL), ampicillin (AMP at 2 g/mL), cefazolin
(CZOL at 8 g/mL), piperacillin (PP at 32 g/mL), tobramycin (TOBRA at 16
g/mL), trimethoprim/sulfamethoxazol (19:1) (TMP/SMX at 8 g/mL). GC
growth control. (21 a) represents the inhibition of planktonic growth at MIC
concentration. (21b) represents the killing effect of antibiotics against
planktonic
forms. (21c) represents the killing effect against mature bio film.
- Figure 22. Killing curves of E. coli CFT073 by antibiotics and
antibiotics associated with 5 g/mL V9T14 biosurfactant. Biofilms (solid line)
and planktonic cultures (hatched line) were exposed to ampicillin (A),
cefazolin
(B), ceftriaxone (C) ciprofloxacin (D), piperacillin (E), tobramycin (F) and
trimethoprim/sulfamethoxazol (19:1) (G) for 24 h in presence (triangle) or
absence (square) of V9T14 biosurfactant. Data for planktonic and biofilm
cultures
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
7
are plotted in units of cfu per milliliter and cfu per peg in the MBECTM
device,
respectively. Planktonic cells and biofilms were estimated by viable cell
count.
Each data point was calculated from a minimum of three replicates and a
maximum of nine and the error bars indicate standard error.
- Figure 23. Influence of V9T14 biosurfactant on antibiotic MIC values
against E. coli CFT073 after 24 h of exposure evaluated by measuring the
OD650õm. OD optical density. Planktonic growth inhibition was evaluated for
antibiotics alone (solid line) and antibiotics associated with 5 g/mL of
V9T14
biosurfactant (hatched line). Cultures were exposed to ampicillin (A),
cefazolin
(B), ceftriaxone (C), ciprofloxacin (D) piperacillin (E), tobramycin (F) and
trimethoprim/sulfamethoxazol (19:1) (G) for 24 h. Each data point was
calculated
from a minimum of three replicates and the error bars indicate standard error.
- Figure 24. CLSM image of Live/Dead stained E. coli CFT073 grown in
the CBD. Images represent the E. coli growth biofilm (24a), treated with 5
g/mL
of V9T14 biosurfactant (24b), treated with 16 g/mL of tobramycin (24c) and
treated with 16 g/mL of tobramicin in the presence of 5 g/mL of V9T14
biosurfactant (24d).
- Figure 25. The figure shows surfactin structure.
- Figure 26. The figure shows fengycin structure.
- Figure 27a and 27b. Influence of V9T14 surfactin and fengycin
fractions on planktonic E. coli CFT073 (27a) and S. aureus ATCC 29213 (27b)
growth. The two fractions were dissolved in PBS and used in a concentration
range from 4-256 g/mL (27a and 27b).
- Figure 28a and 28b. Influence of V9T14 surfactin and fengycin
fractions on biofilm E. coli CFT073 (28a) and S. aureus ATCC 29213 (28b)
growth. The two fractions were dissolved in PBS and used in a concentration
range from 4-256 g/mL. Biofilm was grown at 37 C for 24 h under shearing
forces (28a and 28b).
- Figure 29a, 29b and 29c. Silver susceptibility after 2 h (29a), 8 h (29b)
and 24 h (29c) exposure. E. coli biofilm was grown 24 h on the pegs of the CBD
and then exposed to silver and silver + V9T14 (SV9) solutions. AgNO3 dilutions
were prepared in Minimal Salts Vitamins Glucose (MSVG). V9T14 biosurfactant
was diluted in MSVG and added to a final concentration of 5 gg/mL.
- Figure 30. Short time (2 h) exposure of a 24 h-old E. coli biofilm to pre-
prepared silver and SV9 solutions (48 h before). V9T14 biosurfactant was
diluted
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
8
in MSVG, as well as AgNO3. Final concentration of V9T14 added to each well
was 5 gg/mL.
- Figure 31. Short time (2 h) exposure of a 48 h-old E. coli biofilm to
freshly-prepared silver and SV9 solutions. V9T14 biosurfactant was diluted in
MSVG, as well as AgNO3. Final concentration of V9T14 added to each well was
5 gg/mL.
- Figure 32 and 33. These figures correspond to Figure 22, wherein the
experimental data have been graphically reproduced in a clearer manner for a
better understanding by the reader.
Figure 34. Killing curve of planktonic E. coli CFT073 by silver, V9T14
biosurfactant, and silver associated with V9T14 biosurfactant after 24h of
exposure.
Figure 35. Polycide susceptibility of different microorganisms after 30
min exposure. Biofilms were grown 24 h on the pegs of the CBD and then
exposed to Polycide and Polycide associated to V9T14 biosurfactant. V9T14
biosurfactant was added to a final concentration of 5 gg/mL.
Figure 36. Copper susceptibility of P. aeruginosa PA14 and S. aureus
ATCC25923 after 8 h exposure. Biofilms were grown 24 h on the pegs of the
CBD and then exposed to copper and copper associated with V9T14
biosurfactant. V9T14 biosurfactant was added to a final concentration of 5
gg/mL.
Figure 37. Silver susceptibility of P. aeruginosa PA14 after 8 h exposure.
Biofilms were grown 24 h on the pegs of the CBD and then exposed to silver and
silver associated with V9T14 biosurfactant. V9T14 biosurfactant was added to a
final concentration of 5 gg/mL.
Detailed description of exemplary embodiments
In the following description, numerous specific details are given to provide
a thorough understanding of embodiments. The embodiments can be practiced
without one or more of the specific details, or with other methods,
components,
materials, etc. In other instances, well-known structures, materials, or
operations
are not shown or described in detail to avoid obscuring aspects of the
embodiments.
Reference throughout this specification to "one embodiment" or "an
embodiment" means that a particular feature, structure, or characteristic
described
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
9
in connection with the embodiment is included in at least one embodiment.
Thus,
the appearances of the phrases "in one embodiment" or "in an embodiment" in
various places throughout this specification are not necessarily all referring
to the
same embodiment. Furthermore, the particular features, structures, or
characteristics may be combined in any suitable manner in one or more
embodiments.
The headings provided herein are for convenience only and do not
interpret the scope or meaning of the embodiments.
This disclosure shows that a biosurfactant producer belonging to Bacillus
licheniformis group, isolated and purified from an organic ammendant, is able
to
produce very efficient and effective biosurfactant.
The new Bacillus licheniformis strain named V9T14 was isolated from the
organic ammendant Enzyveba Nucleobase 2 (EN2) commercialized by Marcopolo
Engineering S.p.A. and was deposited with the Deutsche Sammlung von
Mikroorganismen and Zellkulturen on January 10, 2008 with accession number
DMS 21038 in accordance with Budapest Treaty.
Monitoring the surface tension during growth of V9T14, the present
inventors observed that biosurfactant was produced at the end of the
exponential
phase. V9T14 growth was observed both at 5% and 10% NaCl but less at 10%,
however, biosurfactant was produced only up to 5%.
V9T14 produced a biosurfactant that showed a good effectiveness and
efficiency, defining effectiveness as the lowest value to which the surface
tension
can be reduced and efficiency as the concentration required to reach the
critical
micelle concentration (CMC) value.
The biosurfactant composition produced by V9T14 strain comprises
surfactin and fengycin as witnessed by infrared spectra analysis and mass
spectrometry analysis. The infrared spectra analysis conducted on V9T14
biosurfactant confirmed that this substance was lipopeptide compound. Mass
spectrometry analysis of V9T14 biosurfactant showed principally two groups of
molecules, belonging to surfactin and fengycin metabolites and differing for
homologue and isoform compositions. surfactin group represents about 70-84%
by weight of the biosurfactant composition and fengycin group represents about
16-30% by weight.
surfactin family showed three main homologues (MW 1008, 1022, 1036)
that differ for the length of fatty acid chain, C13, C14 and C15,
respectively. If the
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
areas under the peaks eluted between 16 and 22 min (Figure 18) are summed to
give the total surfactin peak areas for the surfactin family of V9T14
biosurfactant,
a relative surfactin content C13:C14:C15 ratio range of 15-29%:9-23%:54-69% is
obtained. These data compared with commercial surfactin (Sigma) revealed
5 different relative abundances of these main homologues, wherein the relative
surfactin content C13:C14:C15 ratio (Sigma standard) is equal to 1%:50%:49%.
Results obtained by ESI-MS/MS on fengycin molecules showed the
presence of precursor ions and product ions with m/z similar to those observed
by
Wang et al. (2004); it is possible to deduce that the molecules at MW 1477 and
10 1505 present in V9T14 biosurfactant are as C17 fengycin A and C17 fengycin
B,
respectively.
Results obtained by HPLC-MS/MS showed many fengycin lipopeptides of
families A and B. Regarding retention times, molecular weight and product scan
ions fengycin lipopeptides are divided in their families. fengycin relative
composition of family A and family B inside biosurfactant V9T14 shows that C17
fengycin A and C17 fengycin B represent the more abundant homologues inside
their families. More specifically, C17 fengycin A is present in an amount in
the
range 15-35% by weight and C17 fengycin B is present in an amount in the range
45-65% by weight with respect to the total weight of the composition fengycin
molecules.
The present disclosure showed, then, that NaCl concentration inhibited the
production of surface active agents from B. licheniformis V9T14 at 10% NaCl.
Extracted V9T14 biosurfactant showed high stability at NaCl concentration up
to
saturation, with its maximum activity at salt saturation. Moreover, the
biosurfactant had high stability over a wide range of pH (from 5 to 11),
reaching
the maximum surface activity at pH 5.
The surface tension of an aqueous solution of this biosurfactant
composition reached 26 mN/m at 500 g/mL. At CMC value, surface tension was
about 30 mN/m.
Because biofilm formation by hazardous bacteria on biotic and abiotic
surfaces is a serious and sometimes life-threatening problem the biosurfactant
V9T14 has very interesting properties to reduce the hazardous effects of
biofilms.
The present disclosure, thus, provides demonstration that such a
biosurfactant composition, optionally combined with at least one biocide, is
suitable for preventing and/or treating infections caused by bacteria able to
grow
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
11
both planktonically and/or as a biofilm on surfaces of abiotic (i.e.
artificial
surfaces) and biotic types (i.e. animal or human tissues).
The biosurfactant composition, optionally combined with at least one
biocide, can be applied (optionally as a coating) to a surface in any of
liquid,
powder, solid, semisolid and/or gaseous forms. The term "gaseous" means any
form like vapour, gas, volatile. The term "semisolid" means any form like
cream,
paste, gel, etc.
The biosurfactant composition, optionally combined with at least one
biocide, can be applied (optionally as a coating) to the surfaces of medical
devices
as, for example, catheters, implants, prostheses, hip prostheses, knee joint
prostheses, spinal column implants, osteosynthesis implants, orthopaedic
implants, dental implants, breast prostheses, reconstructive implants,
vascular
prostheses, catheter chambers, gastric balloons, gastric rings, gynaecological
devices, intracranial clips.
The biosurfactant composition, optionally combined with at least one
biocide, can also be applied topically on skin and/or mucosa of a patient.
Such a
composition can be in the form of gel, cream, ointment, lotion, spray, salve,
ophthalmic drop, ear drop, irrigation fluid, shampoo, or can be directly
applied to
bandages, plasters, etc. for the treatment of the skin and/or mucosa of a
patient
suffering of a bacterial infection.
With the term "biocide" is meant a chemical substance capable of killing
living organisms, usually in a selective way. Some substances used as biocides
are
also employed as anti-fouling agents or disinfectants under other
circumstances:
chlorine, for example, is used as a short-life biocide in industrial water
treatment
but as a disinfectant in swimming pools. Many biocides are synthetic, but a
class
of natural biocides, derived from e.g. bacteria and plants, includes brassica
oleracea, brassica oleracea gemmifera, and clostridium botulinum bacteria. To
the class of biocides belong antimicrobial agents like germicides,
antibiotics,
antibacterials, antivirals, antifungals, antiprotozoals and antiparasites.
The present disclosure showed the effects of the biosurfactant composition
produced by the new V9T14 strain on i) inhibition of biofilm formation and ii)
removal of bacterial colonization from polystyrene surfaces.
The extent of adhesion of four microbial strains on polystyrene in the
presence or absence of the V9T14 biosurfactant was analyzed using the Calgary
Biofilm Device under shear forces. The results obtained by precoating of the
pegs
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
12
prior to inoculation showed that this was just as effective as including
biosurfactant in the growth medium. A reduction of 97% was observed for
biosurfactant V9T14 against E. coli CFT073.
V9T14 lipopeptide biosurfactant can inhibit biofilm formation through
binding to cell surfaces or to cell surface components, thereby influencing
the
outer membrane hydrophobicity.
This is the first time that the biosurfactant fengycin has been demonstrated
to be able to prevent adhesion of the biofilm produced by a pathogenic E.coli
since its activity until now has been shown only against planktonic E.coli and
mainly against phytopathogenic fungi.
A synergistic activity of several antibiotics associated with V9T14
biosurfactant was demonstrated in the present disclosure as a highly effective
biofilm eradication approach. In the case of planktonic cells, the results
demonstrated an increase of bactericidal activities in the presence of
biosurfactant
at low concentration of ampicillin, cefazolin and ceftriaxone, followed by a
rapid
decline leading to complete killing of all microbial cells as the
concentration was
increased. Ciprofloxacin and trimethoprim/sulphamethoxazol showed a decrease
of planktonic bacterial viable cell count as well, yet complete eradication
was not
obtained under the conditions explored. For each of these antibiotics, with
the
exception of cefazolin, growth inhibitory effects were not modified.
Bactericidal
action of tobramycin, the only aminoglycoside tested, against planktonic forms
does not seem to be influenced by the presence of V9T14 biosurfactant. While
the
inhibitory efficacy was increased, the MIC of cefazolin was reduced from 16 to
8
g/mL.
In the case of adherent biofilm cells, complete eradication was observed
for the association of V9T14 biosurfactant with ampicillin. Reduction of
biofilm
population ranging from 0.5-1.7 log was observed with all the other
antibiotics
tested. The concentration of antibiotics associated with biosurfactant was
decreased to obtain the same cell reduction observed using the antibiotic
alone.
V9T14 biosurfactant action lies in its interaction with biofilm EPS and
bacterial membranes, increasing the activity of antimicrobial agents by
forming
pores in the outer membrane and by facilitating the entrance of antibiotics
through
the EPS of the biofilm.
The present disclosure demonstrates that the co-administration of V9T14
biosurfactant with different antibiotics led to a strong positive synergy
between
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
13
the two molecules in biofilm cell eradication. The effect was that for the
majority
of antibiotics tested the MBEC99.9% was decreased significantly. Also, the
bactericidal effect on planktonic cells (MBC99.9%) was influenced by the
presence
of the two agents together, while the MIC seemed unaffected for the majority
of
antibiotics tested.
The present disclosure, further, demonstrates that the co-administration of
V9T14 biosurfactant with silver, copper and quaternary ammonium compounds
(exemplary compounds of inorganic biocides) led to a strong positive synergy
between the two molecules in biofilm cell eradication of different
microorganisms. V9T14 biosurfactant reduces the "restricted penetration" of
metals through the EPS, increasing metal concentration in the core of the
biofilm.
In addition, V9T14 interacts with the bacterial membrane forming pores and
altering the membrane integrity, allowing for Ag+ or Cu2+ to more freely
penetrate
the cell. Moreover, the presence of the negatively charged amino acids ring
limits
the interaction between metal ions and the EPS. This could lead ultimately to
an
increase of metal entrance into the EPS and the outer membrane of bacterial
cells,
enhancing the activity of metal ions.
The presence of V9T14 biosurfactant increases the efficacy of silver ions
in biofilm killing and reduces biofilm population below the detection limit.
Concentration of silver in the solution containing V9T14 biosurfactant and
silver
needed to obtain this reduction in E. coli CFT073 biofilm was 258-fold less
that
the concentration of silver alone. The present inventors also observed that
the
combination of silver and V9T14 completely killed planktonic cells after 24 h
at a
concentration 64-fold less than that of silver alone. The present data also
further
confirm that exposure time plays a key role in biofilm removal.
This is the first time that a synergistic interaction between silver and a
lipopeptide biosurfactant was observed. Therefore, the activity of silver and
V9T14 biosurfactant is useful in disinfection of surfaces to reduce bacterial
colonization and consequent spreading of diseases.
Materials and Methods
Isolation, culture conditions and biosurfactant screening
The strain V9T14 was isolated from the organic ammendant Enzyveba
Nucleobase 2 (EN2) (Marcopolo Engineering S.p.A, Borgo San Dalmazzo, Italy).
Morphological characteristics were defined by observation at the
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
14
stereomicroscope and performing Gram staining on an overnight culture on
NA+Mn2 media. Identification was performed by using the GP-ROD-SB
BIOLOG assay (Microlog, U.S.A). The V9T14 strain was stored at -80 C in LB
broth (Fluka) supplemented with 30% glycerol. The isolate V9T14 was deposited
by Marcopolo Engineering S.p.A. with the Deutsche Sammlung von
Mikroorganismen and Zellkulturen with accession number DMS 21038 on
January 10, 2008 in accordance with Budapest Treaty.
For biosurfactant screening, one colony of an overnight culture of the
strain V9T14, grown on LB agar at 28 C, was inoculated into 10 mL of LB broth.
Cultures were incubated on a rotatory shaker at 200 rpm for 24 h at 28 C.
Thereafter, cell suspension was centrifuged at 10000 x g for 5 min and the
supernatant was assayed for the presence of surfactant by using the oil
spreading
method as disclosed in Morikawa et al. (2000).
Amylase and cellulase production
To determine the amylase production, the V9T14 strain was grown on a
Petri dish containing M9 agar medium added with 0.5% starch (Waldeck et at.,
2007). After incubation, plates were overlayed with Lugol solution. For
cellulase
production, the strain was grown on a Petri dish containing M9 agar medium
added with 0.5% carboxymethyl cellulose. Plates were incubated at 28 C for 24
and 48 h. After incubation, plates were overlayed with Congo red solution
(0.1%w/v). Enzyme production was estimated by measuring the area of the halos
around a single colony.
Oil spreading
Oil spreading assay (Morikawa et at., 2000) was performed by using 20
L of Motor Oil IOW-40 (Selenia) previously deposited onto the surface of 20 mL
of distilled water in a Petri dish (90 mm in diameter) to form a thin
membrane.
Twenty microliters of bacterial supernatant were gently put onto the centre of
the
oil membrane. Diameters of clearly formed oil displaced circles were measured
to
determine the presence of biosurfactants.
Bacterial halotolerance and biosurfactant production
The V9T14 strain was inoculated in LB broth with 50 and 100 g/L of NaCl
and incubated at 28 C for 48 h. Bacterial growth was monitored at OD595nm,
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
biosurfactant production was estimated by the measurement of the surface
tension
assessed with a Sigma 703D tensiometer (KSV) equipped with a du Nouy
platinum ring.
5 Biosurfactant extraction and enrichment
For biosurfactant production, seed culture was prepared by transferring a
loop of the V9T14 strain from a LB agar overnight culture into 10 mL of LB
broth
and incubated at 28 C for 4 h at 200 rpm. Thereafter, 2 mL were inoculated in
500
mL of LB broth in a 2000 mL flask and incubated again at 28 C for 24 h at 120
10 rpm. The overnight liquid culture was centrifuged at 8000 x g for 30 min
and the
supernatant was collected. Bacterial pellet was resuspended in distilled water
and
centrifuged again at 8000 x g for 30 min. Supernatants were pooled, acidified
to
pH 2 with 6 N HC1, stored at 4 C overnight and extracted with ethyl
acetate/methanol (4:1) three times. The organic fraction was evaporated to
dryness
15 under vacuum condition, acetone was added to recover the raw biosurfactant.
Acetone was evaporated and the biosurfactant was collected and weighed. Within
the present disclosure, the term V9T14 refers to the extracted V9T14
biosurfactant.
Surface tension and Critical Micelle Concentration
To measure the surface tension between biosurfactant solution and air, a
purified biosurfactant solution was prepared in alkaline sterile demineralized
water at 500 g/mL. Measurement was carried out at 24 C 0.5 in triplicate
with
a K10 tensiometer (Kress GmbH, Hamburg, Germany) equipped with a du Nouy
platinum ring. Distilled water was used for calibration. Twenty milliliters of
biosurfactant solution were used for each measurement; the ring was placed
just
below the surface of the solution, subsequently the force to move this ring
from
the liquid phase to the air phase was determined in triplicate.
Critical Micelle Concentration (CMC) was determined on serially diluted
biosurfactant solutions in alkaline distilled water. Surface tension of each
dilution
was determined in triplicate. Maximal standard deviation admitted to surface
activity measurements was 0.30 mN/m. The CMC of the biosurfactant was
estimated from the intercept of two straight lines extrapolated from the
concentration-dependent and concentration independent sections of a curve
plotted between biosurfactant concentration and surface tension values.
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
16
Stability studies
The effect of different parameters on the surface activity of the extracted
biosurfactant produced by V9T14 strain was determined. Solutions of extracted
biosurfactant were prepared in distilled water at 100 g/mL (final pH adjusted
to
7.0 with 1 N NaCl) containing different concentrations of NaCl ranging from 0%
to saturation (about 35%) and the surface tension was measured. The pH of the
purified biosurfactant water solutions was adjusted to different values,
ranging
from 2.3- 10.3, using 3 N NaOH or 3 N HC1 and surface tension was measured.
Each measure was made in triplicate and the average and standard deviation
were
calculated.
FT-IR spectrometric analyses
Fourier Transform Infrared (FT-IR) absorption spectrometry was used to
define the structure of V9T14 biosurfactant. FT-IR spectra were obtained with
a
Thermo Nicolet Avatar 370 FT-IR spectrometer equipped with a diffuse
reflectance accessory. One milligram of the sample was mixed thoroughly with
100 mg of homogenised porcelain-milled KBr (FT-IR grade). A pellet was
prepared using a press. The pellet was immediately put into the sample holder
and
FT-IR spectra were recorded. Data were collected and processed with Ez Omnic
software. FT-IR scanning was conducted in ambient conditions. The resolution
was set to 4 cm -1 and the operating range was 500-4000 cm 1. Sixty-four
spectra
per sample were recorded, averaged for each spectrum and corrected against the
spectra of pure KBr and ambient air as background.
Thin-layer chromatography
Analytical thin-layer chromatography (TLC) was carried out on pre-coated
silica gel 60 F 254 plates (Merck Co. Inc, Damstadt, German). TLC plates were
spotted with the sample extracted biosurfactant dissolved in methanol and
developed using the following mobile phase: methanol: chloroform: acetic acid,
89:9:2, by vol. (1) and chloroform:methanol:water, 65:25:4 by vol. (2).
Substances were visualized by spraying chromatograms both with non specific
reagent (such as 4% potassium permanganate followed by charring at 170-180 C)
and with reagents specific to detecting peptides and free amino groups (such
as
with 2% ninhydrin solution in butanol followed by heating at 110 C).
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
17
Silica gel chromatography
The V9T14 biosurfactant extract (150 mg), purified according the method
previously described, was chromatographed on a column of silica gel (0,046-
0,066 gm; Merck KGa) (40 g). Elution was carried out with chloroform and then
with chloroform-methanol mixture with the methanol concentration gradually
increased from 10% to 100%. The process was monitored by TLC in solvent
system (1). Five main samples (A-E) have been collected and successively
analyzed by MS and HPLC/MS. Two main samples are reported: sample B (42.9
mg) and sample D (33.8 mg).
Determination of the lactone bond
To determine the lactone linkage 1 mg of lipopeptides of sample D was
dissolved in 1 M potassium hydroxide (KOH) solution and allowed to react
overnight at room temperature. Excess KOH was neutralized and the hydrolysate
was desalted for mass spectrometry analysis.
Mass spectrometry analysis
An aliquot of V9T14 biosurfactant dried material was dissolved in
methanol/acetonitrile (50/50 v/v) to obtain a 1000 gg/mL stock solution.
Freshly
prepared intermediated stock solutions were made by diluting the stock
solution
with methanol/water (50/50 v/v) to 15 gg/mL solutions.
All mass spectrometry analyses were performed using a LCQ DECA XP
Plus (Thermo Finnigan, San Jose, USA) Ion Trap mass instrument equipped with
an electrospray ion source. Samples (15 g/mL solutions) were infused with a
syringe. The electrospray source was operated, respectively, at a capillary
voltage
of 21 V and a spray voltage of 5.3 kV in positive ion mode, and at 15 V and -5
kV
in negative ion mode; capillary temperature was set at 350 C. MS full scans in
positive and negative ion modes in the range 100-2000 m/z were acquired. ESI-
MS/MS analysis was also used. The target ionized molecules or sodium-ionized
molecule were selected and then fragmented and the product ions were recorded.
Liquid chromatography-Mass spectrometry analysis
A Surveyor HPLC coupled on line to a LCQ DECA XP Plus (Thermo
Finnigan, San Jose, USA) Ion trap mass spectrometer equipped with an
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
18
electrospray ionization source (ESI) was employed. Separations were performed
using a precolumn: (Security guard cartridges) C18 Phenomenex 4 mm x 3.0 mm
and a column: C18 Luna, Phenomenex, 150 mm x 4.5 mm, 5 m. The mobile
phase components were: A = water, 1% formic acid; B = acetonitrile; the
lipopeptides were eluted according to the following linear gradient: A:B
(50:50)
for 3 min, then A:B (0:100) over 18 min and then 100% B over 5 min at a flow
rate of 0.8 mL/min; MS full scan positive and negative ion modes in the range
100-2000 m/z were performed; alternatively ESI-MS/MS was applied to the
selected precursor ions.
Biosurfactant stock solution for biological assays
V9T14 biosurfactant was dissolved in PBS (pH 7.2) at the final
concentration of 5120 g/mL and the final pH was adjusted to 7.0 by using 6 N
NaOH or 6 N HC1. These solutions were filtered through 0.2 m filters and then
stored at 4 C. Stock solutions of V9T14 biosurfactant were diluted at a ratio
of
1:1 in PBS.
Biocides.
The term biocide includes any chemical substance capable of killing living
organisms. Within the present disclosure biocides are to be considered
including
antibiotics, antibacterials, germicides and also inorganic compounds having
the
ability of killing at least bacteria.
The inorganic compounds encompassed in the present disclosure with the
term biocide can be i.e. Sodium selenite (Na2SeO3; Sigma Chemical Company, St.
Louis, MO), silver nitrate (AgNO3; Sigma), cupric sulfate (CuSO4.5H2O; Fischer
Scientific, Ottawa, Ontario, Canada), zinc sulfate (ZnSO4.7H2O; Fischer
Scientific), and aluminum sulfate [A12(SO4)3.18H2O; Fischer Scientific).
The antibiotics encompassed in the present disclosure are i.e. ampicillin,
cefazolin, ciprofloxacin, ceftriaxone, tobramycin and
trimethoprim/sulfamethoxazol.
Other biocides advantageously used in combination with the biosurfactant
composition of the present disclosure are Polycide (Pharmax Limited, Toronto,
Ontario, Canada), Virox (Virox Technologies Incorporated, Oakville, Ontario,
Canada), Stabrom 909 (Albemarle Corporation, Richmond, VA), isopropyl
alcohol (Sigma), benzalkonium chloride (alkyldimethylbenzyl ammonium
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
19
chloride; Sigma), cetalkonium chloride (cetyldimethylbenzyl ammonium chloride;
FeF Chemicals, Denmark), cetylpyridinium chloride (cetyldimethylpyridyl
ammonium chloride; FeF Chemicals), and myristalkonium chloride
(tetradecyldimethylbenzyl ammonium chloride; FeF Chemicals).
Stock solutions of metals and biocides
Polycide (Pharmax Limited, Toronto, Ontario, Canada) was diluted in PBS
to 2.5% (13250 ppm benzalkonium chloride) (2 x the recommended concentration
suggested by the manufacturer). Metals were dissolved in double distilled
water
(ddH2O). AgNO3 (Sigma) was dissolved in ddH2O to 150 mM; CuS04 (Fischer
Scientific Ottawa, Ontario, Canada) was dissolved in ddH2O to a final
concentration of 500 mM.
All solutions were sterile filtered and stored at 4 C. Antibiotics were
diluted in ddH2O at the final concentration of 1024 gg/mL. Working
concentrations for antibiotics and biocides are summarized in Table 1. Serial
two-
fold dilutions were performed to create the challenge plate (see below).
Table 1.
Dilution Working
Chemical agents Exposure time medium concentration
Polycide 30 min PBS 2.5 %
2h - 8h MSVG
Ag+ 24h 15 mM
Cu ++ 2h - 8h MSVG 50 mM
Bacterial biofilm
Biofilms were grown in the Calgary Biofilm Device (CBD, Innovotech,
Edmonton, AB, Canada) as described by Harrison et al. (2006). The CBD consists
of a polystyrene lid with 96 pegs that may be fitted inside a standard 96-well
microtiter plate. Each peg of the CBD has a surface area of approximately 109
mm . For the anti-adhesion experiments, frozen stocks of four bacterial
pathogens
were used.
E. coli CFT073 was streaked on LB agar, S. aureus ATCC 29213 and P.
aeruginosa PA14 on TSA and the isolate S. epidermidis on Cathion-Adjusted
Mueller-Hinton agar and all incubated overnight at 37 C. A second fresh
subculture of each microbial strain was grown overnight at 37 C on the
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
appropriate agar medium. Using a cotton swab, colonies from this fresh
secondary
subculture were suspended in the respective broth medium to match a 1.0
McFarland standard, corresponding to approximately 3.0 x 108 cfu/mL. This
suspension was diluted again 30-fold in broth to create the inoculum for the
CBD,
5 that was approximately 1.0 x 107 cfu/mL. Then, 150 L of the bacterial
inoculum
were added to each well of a 96-well microtiter plate. The CBD peg lid was
then
fitted inside of this and the assembled device was placed on a gyrorotary
shaker at
150 rpm in a humidified incubator for 24 h. Following the period of
incubation,
biofilms were rinsed twice by inserting the peg lids into microtiter plates
with 200
10 L/well of 0.9% saline for 2 min to remove loosely adherent cells.
For coating experiments, the CBD was previously coated with biosurfactant by
dipping the lid of the CBD into 200 L of the stock solution and its dilutions
previously put in each well of a microtiter plate. The CBD was incubated at 37
C
on a rotatory shaker at 125 rpm for 24 h, then removed from the microtiter
plate
15 and dried under the hood for 1 min before adding it to the bacterial
inoculum.
In another set of experiments, the CBD was used uncoated and microbial
inoculum was distributed in each well together with biosurfactant stock
dilutions
to reach concentration ranges from 1-20 g/well (5-100 g/ mL) in the final
volume of 200 L.
Strains and growth media for silver
All the microbial strains used in this work are summarized in Table 2.
Strains were stored at -70 C in Microbank vials (ProLab Diagnostic, Toronto,
Canada) according to the manufacturer's directions. E. coli strains were grown
in
Luria Bertani agar (LB, EMD Chemicals Inc.), all the other microorganisms were
cultivated in Tryptic Soy Agar (TSA, EMD Chemicals Inc.). All microorganisms
were incubated for 24 h at 37 C. E. coli biofilms were cultivated in LB broth,
all
the other biofilms were grown in Tryptic Soy Broth (TSB, EMD Chemicals Inc.)
and all serial dilutions were performed using 0.9% NaCl. Susceptibility
testing of
biocides was performed in phosphate buffered saline (PBS) or Minimal Salts
Vitamins Glucose (MSVG) (Table 2).
According to Teitzel and Parsek (2003), MSVG contained 1 g/L
(NH4)2SO4, 0.06 g/L MgSO4.7 H20, 0.06 g/L CaC12, 0.02 g/L KH2PO4, 0.03 g/L
Na2HP04.7 H20, 2.384 g/L HEPES, 1 mL of 10 mM FeS04 and 0.990 g/L
glucose. The pH was adjusted to 6.5 and autoclaved. Then 1 mL of Trace
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
21
Vitamins Solution (TVS) was added. TVS contained 20 mg/L biotin, 20 mg/L
folic acid, 50 mg/L thiamine HC1, 50 mg/L D-(+)-calcium pantothenate, 1 mg/L
vitamin B12 (cyanocobalamina), 50 mg/L riboflavin, 50 mg/L nicotinic acid, 100
mg/L pyridoxine HC1, 50 mg/L of p-aminobenzoic acid (PABA). TSV solution
was sterile filtered (0.2 gm) and stored at 4 C in the dark.
Table 2.
Mean biofilm
Strains cell densitya (logio
CFU/peg)
Entero hemorrhagic Escherichia coli (EHEC)
E. coli 0157:H7 4.3 0.2
Uropathogenic Echerichia coli (UPEC)
E. coli CFT073 6.4 0.4
Methicillin Sensible Staphylococcus aureus (MSSA)
S. aureus ATCC 25923 (SA25923) 5.2 0.3
Pseudomonas aeruginosa (PA)
P. aeruginosa PA14 6.0 0.5
a Starting cell density measurements were based on the means and standard
deviations of the
pooled, log-transformed data after 24 h of growth.
The strains tested are publicly available by the Department of Biological
Sciences, University of Calgary, 2500 University Drive NW, Calgary AB T2N
1N4 Canada.
Viable cell counting
The effect of the V9T14 biosurfactant was assessed by determining the
viable cell counts after biofilms had been rinsed as described above. The lid
of the
CBD was then inserted into 200 L of LB broth added with 1% Tween 20 in the
wells of a microtitre plate. Biofilms were disrupted from the peg surface
using an
Aquasonic 250T ultrasonic cleaner (VWR International, Mississauga, ON,
Canada) for 10 min. The disrupted biofilm cells were serially diluted in 0.9%
saline, and then plated onto LB agar. Agar plates were incubated for 24 h at
37 C
and then enumerated. Viable cell counts for planktonic cultures (i.e. starting
inocula and planktonic forms after incubation) were similarly carried out by
serial
dilution in 0.9% saline, and then by plating onto agar as described for
biofilm
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
22
cells.
Susceptibility testing with combinations of biosurfactant and antibiotics
Antibiotics tested were ampicillin, cefazolin, ciprofloxacin, ceftriaxone,
piperacillin, tobramycin and trimethoprim/sulfamethoxazol (19:1) used at
concentrations starting from 2 x MIC, alone and in combination with V9T14
biosurfactant. Antibiotics were serially diluted (loge) using 0.9% saline in a
96-
well microtiter plate, and then a solution of biosurfactant was added to each
well
to reach a final concentration of 5 g/mL.
E. coli CFT073 biofilms were grown on the CBD at 37 C for 24 h in a
rotatory shaker at 130 rpm, as described above. Then CBD lid was rinsed twice
with 0.9% saline, exposed to the antibiotics and antibiotic plus biosurfactant
microtiter plate and incubated at 37 C, 125 rpm for 24 h. After exposure, the
CBD
was removed and the 96-well microtiter plate was used to estimate minimal
inhibitory concentration (MIC) and minimal bactericidal concentration
(MBC99.99%) values. For MIC value, the plate was read using a
spectrophotometer
at 650 nm, MIC was defined as the lowest concentration not presenting
turbidity;
according to the guidelines of the American Clinical Laboratory Standards
Institute, the minimum bactericidal concentration (MBC) is conventionally
defined as a concentration of an antimicrobial agent that kills 3 logio cells
of a
bacterial culture (or 99.9% of the bacteria). In our experiments we used a
more
restrictive criterion, defining the MBC99.99% value, defined as the lowest
concentration of the antibiotic activity higher than 4 logio by viable cell
count.
Minimal biofilm eradication concentration (MBEC99.9%0) was defined as the
lowest
concentration to eradicate 3 logio of the viable microorganisms in a biofilm.
Susceptibility testing with combinations of biosurfactant and biocides
E. coli CFT073 and E. coli 0157:H7 were grown on Luria Bertani agar
(LB, EMD Chemicals Inc.), P. aeruginosa PA14 and S. aureus were grown on
TSB agar. Susceptibility testing of metals was performed in Minimal Salts
Vitamins Glucose (MSVG) according to Teitzel and Parsek (2003), while
Polycide susceptibility testing was performed in Phosphate Buffered Saline
(PBS).
Extracted V9T14 biosurfactant was stored under the chemical hood
providing solvent evaporation until dryness. The biosurfactant powder was
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
23
homogenized using a porcelain mortar and a pestle. V9T14 was dissolved in PBS
and pH was adjusted to 7.5 with 1 N NaOH. Volume was adjusted to match a final
concentration of 5000 gg/mL.
AgNO3 (Sigma) and CuS04 (Sigma) were dissolved in double distilled
water (ddH2O) to 150 mM and 500 mM respectively. Polycide was diluted in PBS
to 25%. Solutions were sterile filtered and stored at 4 C. Working
concentrations
for metals and biocide are shown in Table 1. Serial two-fold dilutions were
performed to create the challenge plate.
Biofilms were grown in the Calgary Biofilm Device (CBD) as described
above. Starting from cryogenic stock, the strain was streaked out twice on
TSA,
and an inoculum was prepared by suspending colonies from the secondary agar
subculture in 0.9% saline to match a 1.0 McFarland standard. This standard
inoculum was diluted 1/30 in LB broth.
150 gL of this inoculum was transferred into each well of a 96-well plate,
and the sterile peg lid of the CBD was inserted into the plate. The inoculated
device was then incubated at 125 rpm, for 24 h at 37 C and 95% relative
humidity. In an alternative set of experiments, biofilms were grown for 48 h
before silver exposure and spent medium was changed with fresh medium after 24
h.
Following this period of incubation, biofilms were rinsed once with 0.9%
saline (200 gL/well) to remove loosely adherent planktonic cells. Biofilm
formation was evaluated by breaking off four pegs from each device after it
has
been rinsed. Biofilms were disrupted from pegs into 200 gL/well of LB
supplemented with 1% Tween 20 using an ultrasonic cleaner for a period of 10
min (Aquasonic model 250T, VWR Scientific, Mississauga, Canada) as described
above. The disrupted biofilms were serially diluted in 0.9% saline and plated
on
LB agar for viable cell counting. An initial set of quality control assays
were
carried out to ascertain that the strain used in this study formed equivalent
biofilm
on the CBD pegs as described in Harrison (2008).
High-throughput susceptibility testing of microbial biofilms
The challenge plate of biocides, antibiotics and biosurfactant was made in
a 96-well plate. Biocides were serially two-fold diluted in PBS and V9T14
biosurfactant was added to each well at the final concentration of 5 L/mL.
Antibiotics were similarly diluted in Muller-Hinton broth, while metals were
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
24
diluted in MSVG. When prepared, each challenge plate had 7 sterility control,
8
growth control, 11 wells containing 5 gL/mL of V9T 14 biosurfactant, 11
different
concentrations of single biocide (or metals) and 11 different concentrations
of
biocide (or metals) associated with 5 gL/mL of V9T14 biosurfactant.
Biofilms that have been grown on lids of the CBD and rinsed once in 0.9%
saline were inserted in the challenge plates. Following the exposure time at
37 C,
biofilms were rinsed once with 0.9% saline (200 gL/well) and then placed in a
microtiter "recovery" plate that contained 200 gL/well of neutralizing medium
(TSB supplemented with 1% Tween 20, 2.0 g/L reduced glutathione, 1.0 g/L L-
histidine, 1.0 g/L L-cysteine). The recovery plate was sonicated for a period
of 10
min (Aquasonic model 250T, VWR Scientific, Mississauga, Canada). The
disrupted biofilms were serially diluted in 0.9% saline and plated on the
appropriate agar medium for viable cell counting. Plates were then incubated
at
37 C overnight and finally enumerated.
To define MBC of biocides, recovery plates were incubated at 37 C for
24-48h and the adsorbance (OD 650nm) was read in a microtiter plate reader.
Confocal laser scanning microscopy (CLSM)
Pegs were broken from the lid of the CBD using pliers (Harrison et al.
2006) and then rinsed once with 0.9% saline to remove planktonic forms. Prior
to
examination by CLSM, biofilms were fluorescently stained with acridine orange
(AO) (Sigma Chemical Co., St. Louis, MO, USA). To stain biofilms, pegs were
immersed in 0.1% w/v AO in PBS for 5 min at room temperature in the dark. To
determine live and dead cell distribution in antibiotic experiments, rinsed
biofilms
were stained with Syto-9 (6.7 M) and propidium iodide (40 M) (Live/Dead
BacLightTM Kit, Molecular Probes, Burlington, ON, Canada) at 30 C for 30 min.
Fluorescently stained biofilms were placed in two drops of 0.9% saline on the
surface of a glass coverslip. These pegs were examined using a Leica DM IRE2
spectral confocal and multiphoton microscope with a Leica TCS SP2 acoustic
optical beam splitter (AOBS) (Leica Microsystems, Richmond Hill, ON, Canada).
To minimize or eliminate artefacts associated with single and/or simultaneous
dual wavelength excitation, all dual labelled samples were sequentially
scanned,
frame-by frame, first at 476 or 488 nm and then at 543 nm. Fluorescence
emission
Awas then sequentially collected in the green and red regions of the spectrum,
respectively. Line averaging (x2) was used to capture images with reduced
noise.
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
A 63 x water immersion objective was used in all imaging experiments. Image
capture and two dimensional projections of z-stacks were performed using Leica
Confocal Software (LCS, Leica Microsystems).
5 Interpretation of results
The efficacy of biofilm adhesion inhibition was assessed by determining
the minimal biofilm eradication concentration (MBEC) after 24 h by mean viable
cell count. Each test was performed at least three times in triplicate on
separate
cultures.
10 The efficacy of antibiotics associated with V9T14 biosurfactant was
assessed by determining the planktonic (MBC99.99%) and biofilm (MBEC99.9%)
killing by mean viable cell count and the MIC value of antibiotics by
absorbance
at 650 nm, after 24 h of exposure. The difference attributed to synergy is
expressed in A values between the logio antibiotic cell count reduction and
the
15 logio association value. "Eradication" was defined as no growth in
antibiotic-free
plates after planktonic culture initially incubated in antibiotic-containing
LB
broth.
Statistical analysis
20 The Student's t test was performed when the aim was to investigate
whether the difference in between the experimental values obtained under
different conditions could be considered significant. To analyze the
significance
of the changes in the logio-transformed raw data, ANOVA statistical analysis
was
performed.
Results
Bacterial isolation
EN2 had a earth-like texture with a culturable population on LB agar
plates ranging from 9.1 x 108 to 1.6 x 109 cfu/g of dry ammendant. From these
plates, more than 400 bacterial colonies were isolated. Forty-five isolates
produced an hemolytic zone in blood agar within 24 h. All the isolates were
grown in LB broth for 24 h and then tested for biosurfactant production with
the
oil spreading method. Fourteen biosurfactant-producing isolates were found and
each of them showed large halos (more than 1 cm diameter). One isolate, V9T14
was selected for further study because of its ability to grow over a wide
range of
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
26
salinity, to show hemolysis and to produce efficient and effective
extracellular
biosurfactant, defining effectiveness the lowest value to which the surface
tension
can be reduced and efficiency the concentration required to reach the CMC
value.
Strain identification and characteristics
Gram stain revealed that V9T14 was spore forming, Gram positive, rod.
By using BIOLOG system and conventional method for GP-ROD-SB
identification, the strain V9T14 was identified as Bacillus licheniformis with
the
probability of 99%, a similarity of 0.639 and a distance of 5.49
Metabolic characteristics of B. licheniformis V9T14 are given in Table 3.
The strain was able to produce amylase and cellulase at 28 after 24 and 48 h
(Fig.
8). B. licheniformis V9T14 showed a high production of both enzymes.
Table 3.
Substrates V9T14 Substrates V9T14
2,3-butanediol + Gentiobiose +
2'-deoxy adenosine + Glycerol +
3-methyl glucose + Glycil-L-glutamic acid +/-
Acetic acid +/- Glycogen +
a-cyclodextrin + Inosine +
Adenosine + Inulin +/-
Adenosine-5'-monophosphate - L-alanine +/-
a-D-glucose + L-alanyl-glycine +/-
a-ketoglutric acid +/- L-arabinose +/-
a-ketovaleric acid +/- L-asparagine +/-
a-methyl-D-glucoside + L-glutamic acid +
Amygdalin +/- L-lactic acid -
Arbutin + L-malic acid +/-
(3-cyclodextrine + L-serine +/-
(3-methyl-D-glucoside + Maltose +
D-alanine +/- Maltotriose +
D-cellobiose +/- m-inositol +
Dextrin + N-acetyl-(3-D-mannosamine +/-
D-fructose + N-acetyl-D-glucosamine +
D-galactose - N-acetyl-L-glutamic acid -
D-gluconic acid + Palatinose +
D-lactic acid methyl ester +/- Pyruvatic acid methyl ester +/-
D-L-a-glycerol phosphate - Pyruvic acid +
D-mannitol - Salicin +
D-mannose + Succinamic acid +/-
D-melezitose + Sucrose +
D-psicose + Thymidine +
Thymidine -5'-
D-ribose + monophosphate +/-
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
27
Substrates V9T14 Substrates V9T14
D-sorbitol +1- Turanose +
D-tagatose - Tween 40 +1-
D-trehalose + Uridine +
Colony appearance of the V9T14 strain is summarized in Table 4.
Table 4.
V9T14
Shape: circular
Edges: entire
LB agar Elevation: pulvinate
Color: yellowish, bright
Consistency: mucous
Shape: circular
Edges: entire
NA+Mn Elevation: raised
Color: pale yellow, bright
Consistency: mucous
B. licheniformis V9T14 produced biosurfactants when grown on LB broth.
The ability of lowering surface tension was verified using a du Nouy platinum
ring digital Tensiometer. Bacteria grown on MSM glucose showed the beginning
of biosurfactant production after 24 h. When grown on LB broth, they showed a
production peak after 24 h at the end of the log phase (figure 1).
Bacillus licheniformis V9T14 was able to grow in the presence of 5%
NaCl and biosurfactant production was not affected by the presence of the
halogen, reaching a surface tension of 36 mN/m after 24 h. Bacterial growth at
10% NaCl was highly slackened and biosurfactant production was inhibited.
Biosurfactant obtained by solvent extraction appeared as amber-coloured
resinous residue, probably due to the presence of small quantity of residual
water
in the extract. After few days at room temperature with low humidity level, it
dried and it was possible to obtain a powder by scratching them with a
spatula.
The biosurfactant had a bad odour. V9T14 solution at 500 tg mL-1 decreased
water surface tension from 68.8 to 26.3 mN/m. Serial dilutions of V9T14
biosurfactant showed a constant surface tension value of 26 mN/m until
concentration of 50 tg mL-1 (figure 2). Then the values slowly increased to
ranges
between 27 and 30 mN/m until the concentration of 10 tg mL-1. The CMC was
calculated as the intercept of two straight lines extrapolated from the
concentration-dependent and concentration independent sections of a curve
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
28
plotted between biosurfactant concentration and surface tension values. The
calculated CMC of V9T14 biosurfactant was 6.7 g mL-1.
FT-IR spectroscopic analysis
The FT-IR spectrum of V9T14 in KBr (figure 9) showed strong absorption
bands indicating the presence of peptides at 3300 cm -1 resulting from N-H
stretching mode at 1655 cm -1 resulting from the stretching mode of the CO-N
bond and the 1535 cm1 resulting from the deformation mode of N-H bond
combined with C-N stretching mode. These results suggest that V9T14
biosurfactant contains peptide like moieties. The bands at 2960 to 2860 and
1470
to 1370 cm -1 resulting from the C-H stretching mode reflect the presence of
an
aliphatic chain (-CH2-, -CH3). The absorption region at 1740 - 1680 cm -1 was
due
to lactone carbonyl absorption.
MS and MS's analysis
Lipopeptides produced by V9T14 were firstly characterized through ESI-
MS positive full scan mode spectra (Figure 10). Two clusters of peaks with 14
or
28 Da difference in their molecular weight are present, revealing two sets of
homologue molecules.
The first set evidence three main peaks at m/z 1058.7, m/z 1044.7 and m/z
1030.7 that correspond to the sodiated molecules m/z M+Na]+ of surfactin-
molecules (Figure 11). Besides, negative full scan mode spectra shows with
three
main peaks at 1034.5 m/z, 1020.5 m/z and 1006.5 m/z that correspond to the
quasimolecular ions M-H]-. Therefore, the molecular weight of the three
molecules is respectively m/z 1036, 1022 and 1008. The three peaks differ of
14
Da, suggesting a difference in the carbon chain length (-CH2-).
The m/z 1058.7, 1044.7 and 1030.7 were used as precursor ion for further
ESI-MS/MS analysis respectively (Figures 12, 13 and 14). The results showed
that the appearance of product ions of these precursor ions had regularities.
Product ions of the precursor ion at m/z M+Na]+ 1058.7 where found at
m/z 1040.4 , 945.5, 832.5, 814.3, 618.2, 707.3, 594.3, 481.2, 463.3 (Figure
12).
Ion at m/z 1040.4 corresponded to losses of water (-18 Da) from m/z M+Na]+
1058.6. The other product ions where identified as two series deriving from
the
initially opening of the lactone ring, one containing the fatty acid chain
(m/z
945.5, 832.5, 814.3, 618.2) and the other one only relative to the peptidic
portion
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
29
(m/z 707.3, 594.3, 481.2, 463.3). Ions at m/z 945.5 corresponded to the loss
of
Leu (-113 Da) and at m/z 832.5 corresponded to the loss of Leu (-113 Da) from
945.5 m/z, while ion at m/z 814.3 corresponded to the loss of Leu-Leu-H20 (-
244
Da) from m/z 1058.6 and ion at m/z 618 m/z corresponded to the loss of Asp-Val-
(-214 Da) from m/z 832. Product ion at m/z 707.3 correspond to the loss of C15
f3-
hydroxyl fatty acid chain-Glu (-352 Da) from m/z M+Na]+1058.6, ion at m/z
594.3 correspond to the successively loss of 1 Leu (-113 Da), ion at m/z 481.2
to
the loss of another Leu (-113 Da) and ion at m/z 463.3 to the loss of Leu-H20
(-
131 Da).
Product ions of the precursor at m/z M+Na]+ 1044.6 where found at m/z
1026.5, 931.4. 818.5, 800.3, 604.2, 707.3, 594.3, 481.2, 463.3 (Figure 13).
Ion at
m/z 1026.5 corresponded to losses of water (-18 Da) from m/z M+Na]+ 1044.6.
Ions at m/z 931.5 corresponded to the loss of Leu (-113 Da) and at m/z 818.5
corresponded to the loss of Leu (-113 Da) from 931.5 m/z, while ion at m/z
800.3
corresponded to the loss of Leu-Leu-H20 (-244 Da) from m/z 1044.6. Ion at m/z
604 m/z corresponded to the loss of Asp-Val- (-214 Da) from m/z 818. Product
ion at m/z 707.3 correspond to the loss of C1o (3-hydroxyl fatty acid chain-
Glu (-
338 Da) from m/z M+Na]+ 1044.6, m/z 594.3 correspond to the successively loss
of 1 Leu (-113 Da), m/z 481.2 to the loss of another Leu (-113 Da) and m/z
463.3
to the loss of Leu-H20 (-131 Da).
Product ions of the precursor at m/z M+Na]+ 1030.6 where found at m/z
1012.5, 917.4, 804.5, 786.3, 590.2, 707.3, 594.3, 481.2, 463.3 (Figure 14).
Ion at
m/z 1012.5 corresponded to losses of water (-18 Da) from m/z M+Na]+ 1030.6.
Ions at m/z 917.5 corresponded to the loss of Leu (-113 Da) and at m/z 804.5
corresponded to the loss of Leu (-113 Da) from 917.5 m/z, while ion at m/z
786.3
corresponded to the loss of Leu-Leu-H20 (-244 Da) from m/z 1044.6. Ion at m/z
590 m/z corresponded to the loss of Asp-Val- (-214 Da) from m/z 804.5. Product
ion at m/z 707.3 correspond to the loss of C1o (3-hydroxyl fatty acid chain-
Glu (-
338 Da) from m/z M+Na]+ 1044.6, m/z 594.3 correspond to the successively loss
of 1 Leu (-113 Da), m/z 481.2 to the loss of another Leu (-113 Da) and m/z
463.3
to the loss of Leu-H20 (-131 Da).
The product ions series containing the fatty acid portion of the precursor
ions m/z 1058.7, 1044.7 and 1030.7 differ for each molecule of 14 Da,
confirming a -CH2 of difference in the fatty acid chain. The product ions
series
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
belonging to the peptidic moiety is equal for all the three homologues. These
data
are in accordance with mass spectra of surfactin standard Sigma.
The second set evidence two main peaks at m/z 1478.4 and m/z 1506.4
that correspond to the quasimolecular ions m/z M+H]+ of fengycin molecules
5 (Figure 15). Besides, negative full scan mode spectra shows two main peaks
at
1476.4 m/z, 1504.4 m/z that correspond to the quasimolecular ions M-H]-.
Therefore, the molecular weight of the two molecules is respectively m/z 1477,
and 1505. The m/z 1478.4 and m/z 1506.4 were used as precursor ion for further
ESI-MS/MS analysis respectively (Figure 16, 17). The results showed the
10 appearance of product ions of m/z 1080 and 966 as precursor ions of m/z
1478.4
(Figure 16), and of m/z 1108 and 994 as precursor ions of m/z 1506.4 (Figure
17).
Product ions at m/z 1080 and 966 can be explained as neutral loses of fatty
acid-
Glu (-398 Da) and fatty acid-Glu-Orn (-512 Da) respectively from the N-
terminus
segment of fengycin-A. Product ions at m/z 1108 and 994 can be explained as
15 neutral loses of fatty acid-Glu (-398 Da) and fatty acid-Glu-Orn (-512 Da)
respectively from the N-terminus segment of fengycin-B. The two peaks differ
of
28 Da, suggesting a difference in the aminoacidic composition of the peptide
(Ala
or Val). These results are in accordance with those observed by Wang et al.
(2004); the precursor ions at m/z 1478.4 and m/z 1506.4 are fengycin A and
20 fengycin B, respectively.
LC-MS analysis
A mass chromatogram of biosurfactant V9T14 eluted from HPLC-ESI-MS
analysis is presented in Figures 18 and 19. It can be observed, in the range
of 3-10
25 min of retention time, the peaks corresponding to the main isoforms and
homologues of fengycin molecules; in the range of 16-22 min three main peaks
of
homologues of surfactin molecules.
Characterizations of lipopeptides surfactin group (Fraction B)
30 Fraction B eluted from silica gel chromatography showed, at TLC control,
positive reaction with non specific reagent 4% potassium permanganate: the
only
spot visualized had the same Rf of surfactin standard (Sigma). The HPLC-ESI-
MS confirmed the presence of mainly three homologues of surfactin at Rt 18.84
min (MW 1008), Rt 20.12 min (MW 1022), Rt 21.16 min (MW 1036),
respectively surfactin C13, surfactin C14 and surfactin C15. The HPLC-ESI-MS
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
31
analysis of surfactin Sigma showed the same composition (same Rt and MW) but
differences in the abundance of the homologues. If the areas of the peaks
eluted
between 16 and 22 min (Figure 18) were summed to give the total surfactin
peaks
area for the surfactin-family of V9T14 biosurfactant, the relative content
surfactin
C13:C14:C15 ratio in the range 15-29%:9-23%:54-69% is obtained (Table 5).
Table 5.
Relative
MW surfactin-type Rt (min) o
content /o
1008 C-13 surfactin 18.84 22.4
1022 C-14 surfactin 20.12 16.3
1036 C-15 surfactin 21.16 61.3
Characterizations of lipopeptides fengycin group (Fraction D)
Fraction D eluted from silica gel chromatography showed, at TLC
control, positive reaction with ninhydrin reactive. The ESI mass spectrum of
fraction D revealed a cluster containing several molecules that were observed
at
M+H]+ m/z = 1449.8, 1463.8, 1477.8, 1491.8, 1505.8 with the more intense at
m/z 1477.8 and 1505.8. The m/z of these peaks showed high similarity to the
fengycin homologues.
To confirm these structures, alkaline hydrolysis was done on the
lipopeptides in fraction D. ESI-MS of the hydrolysate showed two main peaks at
m/z 1495.8 and 1523.8, while the main peaks before the hydrolysis were at m/z
1477.8 and 1505.8, respectively. This mass gain of 18 Da could be assigned to
hydrolysis of a lactone ring. The hydrolyzed peptides were further sequenced
by
ESI-MS/MS experiments: from the product ions obtained from the precursor at
m/z 1523.8 the ring-opened peptide sequence was determined as Side chain-Glu-
Om-Tyr-Thr-Glu-Val-Pro-Gln-Tyr-Ile; from the product ions obtained from the
precursor at m/z 1495.8 the ring-opened peptide sequence was determined as
Side chain- Glu-Orn-Tyr-Thr-Glu-Al-Pro -Gln-Tyr-Ile. These sequence are in
accordance with fengycin B and fengycin A, respectivey (Figure 26).
To go deeply with the ions observed in ESI-MS spectrum of fraction D,
each of these ions was selected as a precursor ion for further HPLC-ESI-MS/MS
analysis. The results showed that the appearance of production of the
precursor
ions had regularities: product ions of m/z 1080 and 966 were found in MS/MS
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
32
spectra of precursor ions of m/z 1435.8, 1449.8, 1463.8, 1477.8, as well as
fengycin A. Product ions of m/z 1108 and 994 were found in MS/MS spectra of
precursor ions of m/z 1463.8, 1477.8, 1491.8, 1505.8 as well as fengycin B.
The above results could allow concluding that lipopeptide biosurfactant in
fraction D was composed of two families of molecules belonging to fengycin A
and fengycin B group as reported in Table 6.
Table 6.
Relative
MW fengycin-type Rt (min) o
content /o
1435 C-14 fengycin A 3.80 0.9
1449 C-15 fengycin A 4.66 2.9
1463 C-16 fengycin A 6.66 3.3
1477 C-17 fengycin A 7.57 25.1
1463 C-14 fengycin B 5.91 0.7
1477 C-15 fengycin B 6.00 4.9
1491 C-16 fengycin B 7.21 7.2
1505 C-17 fengycin B 8.26 55.1
Effect of NaCI concentration and pH
The V9T14 biosurfactant decreased the surface tension at high NaCl
concentration up to saturation (figure 3.a). Initial surface tension of V9T14
biosurfactant solution was 33 mN/m, and remain almost stable for concentration
up to 25% showing values ranging from 31 to 33 mN/m. Then a small decrease to
30 mN/m from 25% to saturation (more than 35%) was observed. CMC showed a
small increase at 5% NaCl, from 6.4 gg/mL to 7 gg/mL, then drastically
decrease
to 0.5 gg/mL at NaCl saturation. The effect of various pH values on
biosurfactants surface activity is shown in figure 3.b. V9T14 biosurfactant
has a
poor surface activity at pH from 2 to 4, decreasing from 71 mN/m to about 40
mN/m; while good surface activity was detected starting from pH 5 to 10 (30 -
33
mN/m), with maximum activity at pH 5 (30 mN/m).
Influence of biosurfactants on biofilm formation by different bacterial
strains
Biofilm formation on CBD by bacterial strains was measured according to
the procedure described by Harrison et al. (2006). The anti-adhesive effect of
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
33
V9T14 biosurfactant was considered positive if, after 24 h of growth, there
was a
>1 logio (90%) difference in the mean of CFU/peg compared to the growth
control. The four strains tested, E. coli CFT073, S. aureus ATCC 29213, P.
aeruginosa PA14 and the clinical S. epidermidis efficiently formed biofilms on
the used media.
The increase of V9T14 biosurfactant concentration, promoted a decrease
in E. coli CFT073 adherent viable cell count, to reach a maximal inhibition of
97% compared to the growth control with a precoating concentration of 2560
g/mL (Figure 4a) or by adding 10 g/well (Figure 4b) of biosurfactant with the
inoculum. Statistical analysis of the biofilm viable cell count in the
presence or
absence of V9T14 showed a significant activity of the biosurfactant (p <
0.0001).
There was no apparent effect on planktonic survivability (figure 6) by the
presence of V9T14 (p=0.46) biosurfactant, at every concentration tested.
V9T14 biosurfactant was not able to inhibit the adhesion of other
microorganisms, in particular S. aureus ATCC 29213, P. aeruginosa PA14 and
the isolate S. epidermidis. Viable cell count showed no difference in
bacterial
population of these microorganisms when V9T14 biosurfactant was present on the
pegs or in the culture broth, even with high concentration of biosurfactant.
Figure 7 presents CLSM images of E. coli CFT073 growth control (figure
7a) and adhesion in presence of V9T14 biosurfactant (figure 7b). E. coli
CFT073
showed a dramatic decrease of adhesion when V9T14 biosurfactant was present
on the peg or in culture broth.
Influence ofsurfactin and fengycin HPLC purified fractions on biofilm
formation
The two fractions of V9T14 biosurfactant, corresponding to surfactin
molecules and fengycin molecules, obtained from HPLC were tested for biofilm
inhibition to define which fraction was responsible for the anti-adhesive
properties
against the strain E.coli CFT073.
surfactin and fengycin showed no activity against planktonic E. coli
CFT073 (Figure 27a), while only surfactin showed activity against planktonic
S.
aureus ATCC 29213, resulting in almost 1 logio inhibition at the concentration
of
256 gg/mL (Figure 27b).
fengycin was able to inhibit E. coli CFT073 biofilm adhesion (Figure 28a)
of about 90-95% (i.e. 1.4 0.2 logio inhibition) starting from the
concentration of
8 g/mL up to 256 g/mL. surfactin too affected the adhesion of E. coli CFT073
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
34
of about 60-70% (i.e. 0.4 0.1 loglO inhibition) from the concentration of 8
g/mL.
fengycin was able to inhibit S. aureus ATCC 29213 (Figure 28b) of about
90% (i.e. 1 logio inhibition) at concentration ranging from 4 to 32 g/mL.
surfactin, on the contrary, was not able to reduce the adhesion of S. aureus
ATCC29213, but increases biofilm adhesion.
Influence of combination of V9T14 biosurfactant with antibiotics on planktonic
and biofilm forms of different bacterial strains
The killing of E. coli CFT073 biofilm and planktonic cultures was
examined by ampicillin and piperacillin (penicillins), cefazolin and
ceftriaxone
(cephalosporins), ciprofloxacin (fluoroquinolone), tobramycin (aminoglycoside)
and trimethoprim/sulfamethoxazol (dihydrofolate reductase inhibitor) alone and
in
association with V9T14 biosurfactant. MIC, MBC99.99% and MBEC99.9% of
antibiotics and/or V9T14 were determined three times each as described in
methods.
A 24 h exposure to V9T14 biosurfactant alone was neither able to remove
or eradicate an E. coli CFT073 biofilm nor to inhibit planktonic growth
(Figure
20) confirming that the inhibitory and the killing effect were absent at the
concentration tested.
A 24 h exposure time of the antibiotics to define the concentration of each
antimicrobial agent leading to complete growth inhibition was examined. The
antibiotic susceptibility values of E. coli CFT073 under the various
conditions are
summarized in Table 7, wherein the tolerance values expressed as MIC,
MBC99.99% and MBEC99.9% of antibiotics (Ab) and antibiotics plus biosurfactant
(AbBs) against E. coli CFT073 for various antibiotics with or without
biosurfactant are reported. MIC was defined as the lowest concentration of
antibiotics presenting turbidity in a bacterial broth culture measured at
OD65onm,
MBC99.99% as the concentration needed to reduce planktonic viable cell count
of 4
logio, MBEC99.9% as the concentration to reduce biofilm viable cell count of 3
login.
Table 7.
Ab Ab AbBs Ab AbBs
Antibiotics MIC MBC 99.99 % MBC 99.99 % MBEC 99.9 % MBEC**99.9%
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
Ab Ab AbBs Ab AbBs
Antibiotics MIC MBC 99.99 % MBC 99.99 % MBEC 99.9 % MBEC**99.9%
Ampicillin 2-4 1-2 1-2 4 0.5 -1
Cefazolin 1 - 2 16 8 >32 8
Cefriaxone 1-2 0.5-1 0.5-1 1-2 0.5-1
Ciprofloxacin 8-16 0.25 - 0.5 0.25 - 0.5 >2 1
Piperacillin >32 >32 >32 >32 >32
Tobramycin 16 - 32 8-16 8-16 2-4 2-4
Trimethoprim/ 8- 16 1 1 1 1
Sulfamethoxazol
MIC values of antibiotics alone, expressed as pg/mL.
"expressed as pg/mL.
Figure 21 shows the effect of antibiotics on both planktonic and biofilm
5 forms at the MIC value without biosurfactant. These data demonstrate the
typical
result of the antibiotics being very effective against the planktonic cells
(figure
21A and 21B) but considerably less effective against the biofilm cells (Figure
21 Q.
A combination of V9T14 biosurfactant and antimicrobial agent was
10 considered synergistic if, at 24 h exposure, there was a >1 loglo (90%)
decrease in
the mean of CFU/peg between the combination of the two agents and the
antibiotic treatment on its own. Figure 15 shows the mean viable cell count of
planktonic and biofilm cultures as a function of concentration of antibiotics.
In all
experiments, biofilm growth control showed an approximate population of 8 X
105
15 cfu/peg, while planktonic cultures were 3 x 108 cfu/mL. Data in Figures 21
and
22 demonstrate that the biosurfactant V9T14 increased the efficacy of several
antibiotics.
Ampicillin (Figure 22A) rapidly killed the vast majority of planktonic
cultures at concentration up to 2 tg/mL. However, a portion (102 cfu/mL) of
the
20 planktonic population survived to ampicillin up to 16 tg/mL (Figure 21a).
For
corresponding biofilm cultures (Figure 22a), a reduction of 3 loglo was
observed
at 4 g/mL, but a subpopulation of 103 cfu/peg remain viable after 24 h
exposure
to the antibiotic alone. The association with V9T14 biosurfactant increases
the
killing of planktonic cells to complete eradication at 8 tg/mL. Also surviving
25 biofilm population was reduced to 101 cfu/peg using only 1 tg/mL of
ampicillin,
enhancing the effect of the antibiotic by 4logio, and sessile forms were
eradicated
at 8 tg/mL. MBC99.99% was not modified by the presence of V9T14 biosurfactant
(Table 5) although the killing efficacy was further increased by 2 loglo.
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
36
MBEC99.9%o value was reduced from 4 to 0.5 - 1 g/mL, and the co-
administration
of ampicillin and V9T14 biosurfactant increased the biofilm removal compared
to
the antibiotic alone. The association of ampicillin and biosurfactant thus
significantly promotes reduction of planktonic and biofilm viable cell
numbers.
Cefazolin (Figure 22B) showed a concentration dependent killing curve
for planktonic forms, killing more than 4 logio cfu/mL at 16 g/mL of
antibiotic
(Figure 21b). Biofilm was reduced about 2.2 logio, but even at the highest
concentration tested was not sufficient to reach an MBEC99.9% value (Figure
22b).
The presence of V9T14 biosurfactant enhanced the effect against both
planktonic
and biofilm populations. MBC99.99% was reduced from 16 to 8 g/mL and the
maximum killing effect observed was increased from 6.9 logio at 32 g/mL of
cefazolin to 8.4 logio when biosurfactant was present in a solution of
cefazolin at
the same concentration, leading to complete eradication of planktonic forms.
MBEC99.9% was decreased from more than 32 to 8 g/mL.
The effect of ceftriaxone is shown in figure 21c and 22c. Planktonic
population was rapidly reduced by 3 logio at 0.5 g/mL and by 7 logio at 1
g/mL
of antibiotic (Figure 21c). Biofilm showed a dose dependent curve, killing 3
logio
of bacterial sessile population at 1 g/mL of antibiotic (Figure 22c). When
ceftriaxone was associated with V9T14 biosurfactant, planktonic killing was
modified only at the highest concentration tested, increasing the efficacy by
only
1.7 logio where no cultivable planktonic cells were detected by the presence
of 2
g/mL of antibiotic. Biofilm irradiation showed a similar trend for antibiotic
alone, and only increased by 0.6 logio in the range 0.25 - 0.5 g/mL, and a
further
increase of 0.6 logio for 2 g/mL, reaching a final enhancement of 1.2 logio.
MBC99.99%o was not modified, while MBEC99.9% was decreased from 1 - 2 to 0.5 -
1 g/mL.
Ciprofloxacin (Figure 22D) showed the highest killing of planktonic forms
at 1 g/mL of antibiotic, with a 6.8 logio reduction, with a concentration
dependent curve up to 1 g/mL, then as ciprofloxacin concentration increased,
no
further reduction was observed (Figure 21d). Biofilm was reduced by 2.0 - 2.5
logio at 1 - 2 g/mL respectively (Figure 22d). V9T14 biosurfactant did not
significantly change the effect on planktonic forms up to 1 g/mL, then it
increase
the killing ability by 1.4 logio at 2 g/mL. Biofilm removal was enhanced by
0.7
logio in the range 0.25 - 0.5 g/mL, and 1.7 logio from 1 to 2 g/mL of
ciprofloxacin associated with biosurfactant. MBC99.99% was not modified while
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
37
MBEC99.9% was decreased from more than 2 to 1 g/mL.
Piperacillin (Figure 22E - comparative example) was able to kill
planktonic forms by 2.7 logio at 4 g/mL, then for further increases in
concentration, no further effect on efficacy was observed (Figure 21e).
Similarly,
the biofilm population was reduced by 1 logio at 4 g/mL with no increase of
killing observed for further increase of antibiotic concentration (Figure
22e). The
presence of V9T14 biosurfactant showed no improvement either in planktonic or
in biofilm population. MBC99.99% and MBEC99.9% values were not affected. The
association of V9T14 biosurfactant and piperacillin was not able to satisfy
our
discrimination criterion for synergy identification.
The effect of tobramycin on E. coli CFT073 biofilm is shown in figures
21f and 22f. A reduction of 1 logio was observed in planktonic cultures up to
8
g/mL of antibiotic, then, the efficacy rapidly increased to complete
eradication of
the planktonic population at 16 g/mL (Figure 21f). For corresponding biofilm
cultures, a decrease of 4 logio was observed, stabilizing the survival
subpopulation
of about 102 cfu/mL at 8 - 16 g/mL (Figure 22f). Adding V9T14 biosurfactant
to
tobramycin solution, no increase of activity was noticed against planktonic
cultures, while the increased efficacy of 1 logio against sessile forms was
observed at 16 g/mL. MBC99.99% and MBEC99.9% values were not modified.
Trimethoprim/sulfinethoxazol (19:1) (Figure 22G) reduced planktonic
cells by 4.5 - 5 logio at 2 - 4 g/mL of antibiotics (Figure 21g). Biofilm
population was reduced by about 3 logio at 1 g/mL, then the reduction of
population decreased a further 2 logio up to 8 g/mL (Figure 22g). A surviving
biofilm population of about 104 cfu remains adherent to the peg of the CBD.
The
presence of V9T14 biosurfactant enhanced planktonic killing by 1.3 logio at 16
g/mL of antibiotics, while biofilm removal was enhanced by 1.5 logio at 2 - 4
g/mL. MBC99.99% and MBEC99.9% values were not modified.
The planktonic growth inhibition corresponding to each antibiotic was not
improved by the presence of 5 g/mL of V9T14 biosurfactant (Figure 23), with
the exception of cefazolin (Figure 23B) for which MIC was decreased from 16 to
8 g/mL and tobramycin (Figure 23f), for which the association with 4 g/mL of
antibiotic was able to significantly inhibit the planktonic growth (OD650
decreased
from 0.31 to 0.18).
CLSM images show a mature E. coli CFT073 biofilm (Figure 24a) after 48
h of growth at 37 C. When the mature biofilm was exposed to V9T14
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
38
biosurfactant for 24 h (Figure 24b), no significant effect was observed. If
the
mature biofilm was exposed to 16 g/mL of tobramycin (Figure 24c), a
significant
killing of biofilm population was shown. When a combination of 5 g/mL V9T14
biosurfactant and 16 g/mL of tobramycin was present in broth culture (Figure
24d), the mature biofilm reduction was further increased.
Influence of combination of V9T14 biosurfactant with biocides on biofilm of E.
coli CFT073
The adhesion of E. coli CFT073 to the peg was 6.3 0.4 login cfu/peg
after 24 h, while 5.9 0.4 logio cfu/peg when V9T14 biosurfactant alone was
present, showing no evidence of bio film removal activity.
After 2 h exposure (Fig. 29a), the presence of V9T14 enhanced the killing
activity of silver by about 0.6 logio at 3.750 mM. After 8 h (Fig. 29b) the
increase
was about 3.2 logio (p=0.03) at the lowest concentration of silver tested
(0.015
mM). After 24 h (Fig. 29.c), SV9 decreased biofilm viable cell count below the
detection limit of the device (< 10 cfu/peg). Using silver alone, the
eradication of
biofilm was observed at 7.5 mM, but when V9T14 biosurfactant was added, the
eradication was at 0.029 mM of silver. At 0.015 mM, viable cell count was also
reduced by 3.0 logio compared to silver alone (p=0.0045).
To explain the observed activity after 24 h, the present inventors first
hypothesized the formation of a coordination complex between the lipopeptide
biosurfactant and the metal ion. To verify this hypothesis, SV9 solution was
prepared 48 h before utilization and stored at room temperature in the dark to
allow a possible reaction between the two compounds. Biofilms were then
exposed to this solution for 2 and 4 h.
After 2 h (Fig. 30), results were comparable to those obtained with the
freshly-prepared SV9 solution. The level of killing was higher than that
observed
in Fig. 28a, with an increase of about 1.1 logio (p=0.03) at 1.875 mM compared
to
silver alone. The effect of silver alone at 15 and 7.5 mM was decreased
compared
to the freshly-prepared silver solution, but the presence of V9T14
biosurfactant
restored its killing efficacy.
At 15 mM, freshly-prepared silver solution produced a precipitate,
justifying the small lack of activity compared to 7.5 mM where the presence of
precipitate was less (Fig. 29a). SV9 produced a precipitate as well. The
precipitation of silver in the 48 h old SV9 was greater than that observed for
the
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
39
freshly-prepared solution. This increased precipitation leads to a decrease in
free
silver ions available for antibacterial activity, giving a possible
explanation for the
diminished activity of 48 h old SV9 compared to the freshly-prepared SV9
solution. Regardless, SV9 showed a lower level of precipitation compared to
silver solution alone, possibly explaining the higher bactericidal activity of
SV9
compared to silver solution (Fig. 30).
After 4 h of exposure, the killing efficacy of silver was increased of about
2.3 logio (p=0.0007). Also in this case, as well as the 2 h exposure, no
reduction
of concentration needed to obtain complete eradication was observed.
The present inventors also investigated the influence of biofilm age on
SV9 activity. To define this, a 48 h-old biofilm was exposed for 2 and 4 h to
silver
and fresh SV9 solutions prepared just before use. At 2 h exposure (Fig. 31),
results were comparable to those observed against the 24 h biofilm after the
short
time of exposure. The killing efficacy of SV9 was increased within the range
from
2.3 (p=0.031) to 3.5 logio (p=0.014) compared to silver solution alone.
Similar
results were observed for 4 h of exposure.
By definition, synergy occurs when two or more discrete agents act
together to create an effect greater than the sum of the effects of the
individual
agents. In principle, synergy allows for a reduction in the quantity of agents
used
in combination yet might still allow for greater antimicrobial activity.
The association of silver ions with the biosurfactant led to an interesting
increase of bactericidal activity after 24 h of exposure. The pre-formulation
of
SV9 solution can increase biofilm removal but it seems not to influence the
concentration needed to eradicate the biofilm after a short exposure time (2
and 4
h). Moreover, results shows that biofilm age does not influence the activity
of
SV9 solution in biofilm removal.
Influence of combination of V9T14 biosurfactant with silver on planktonic
forms
of E. coli CFT073.
In the case of planktonic forms of E. coli CFT073, it was possible to
observe an increase of activity of silver associated with V9T14 biosurfactant
compared to silver alone (Figure 34). It was also observed that V9T14
biosurfactant, at the concentration tested (5 gg/mL) was not able to affect
the
growth of planktonic E. coli CFT073. The complete inhibition of growth in
presence of silver was observed for concentration of metal starting from 7.5
mM.
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
When V9T14 biosurfactant was added to the silver solution, the concentration
of
metal able to inhibit bacterial growth was 64-fold less than that of silver
alone.
Influence of combination of V9T14 biosurfactant with different biocides and
5 metals
Uropathogenic E.coli CFT073
The V9T14 biosurfactant was combined with Polycide to control E. coli
CFT073 biofilm population. The association with the biocide led to an increase
in
biofilm killing (Figure 35).
10 The killing of Polycide with V9T14 was increased of about 0.9 logio,
reducing the Polycide biofilm eradication concentration from 0.313% to 0.010%.
Entero hemorrhagic E.coli 0157:H7
The association of V9T14 and Polycide allows a reduction of Polycide
from 0.020% to 0.010% to obtain biofilm eradication (Figure 35). The maximum
15 increase in efficacy of about 2.9 logio was observed at 0.005% of biocide.
S. aureus 25923
The killing efficacy of Polycide was increased of 1.2 logio when V9T14
was present at 0.020% of biocide (Figure 35).
The concentration of copper to decrease biofilm viable cells below the
20 threshold of detectable count was reduced by about 95% when V9T14 was
present
after 8 h exposure (Figure 36). Maximum reduction of viable cell count was
about
2.4 logio.
P. aeruginosa PA14
The concentration of Polycide to decrease biofilm viable cells below the
25 threshold of detectable count was reduced from 1.250% to 0.156% when V9T14
was present (Figure 35). The maximum reduction in viable cell count of about
1.1
logio was observed at 0.039% of biocide.
The association with metals (silver or copper) was effective as well.
Also the concentration of silver required to eradicate the biofilm was
30 decreased from 0.469 mM to 0.117 mM when V9T14 was present (Figure 37).
The concentration of Cue needed to eradicate the biofilm after 8 h of
exposure was decreased from 1.563 mM to 0.391 mM when the metal was
associated with V9T 14, with a maximum increase of killing at 0.195 MM of
about
2.2 logio (Figure 36).
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
41
References
Harrison, J.J., Ceri, H., Stremick, C., Turner, R.J., 2004. Biofilm
susceptibility to metal toxicity. Environ. Microbiol. 6(12), 1220-1227.
Harrison JJ, Ceri H, Yerly J, Stemick CA, Hu Y, Martinuzzi R, Turner RJ,
2006. The use of microscopy and three-dimensional visualization to evaluate
the
structure of microbial biofilms cultivated in the Calgary Biofilm Device.
Biol.
Proced. Online 8(l): 194-215.
Harrison, J.J., Turner, R.J., Joo, D.A., Stan, M.A., Chan, C.S., Allan, N.D.,
Vrionis, H.A., Olson, M.E., Ceri, H. 2008. Copper and quaternary ammonium
cations exert synergistic bactericidal and antibiofilm activity against
Pseudomonas aeruginosa. Antimicrob. Agents. Chemother. 52(8), 2870-2881.
Morikawa, M., Hirata, Y., Imanaka, T., 2000. A study on the structure-
function of lipopeptide biosurfactants. BBA - Mol. Cell. Biol. L. 1488. 211-
218.
Teitzel, G.M., Parsek, M.R. 2003. Heavy metal resistance of biofilm and
planktonic Pseudomonas aeruginosa. Appl. Environ. Microbiol. 69 (4): 2313-
2320.
Waldeck, J., Meyer-Rammes, H., Wieland, S., Feesche, J., Maurer, K.H.,
2007. Targeted deletion of genes encoding extracellular enzymes in Bacillus
licheniformis and the impact on the secretion capability. J. Biotechnol. 130,
124-
132.
Wang, J., Liu, J., Wang, X., Yao, J., Yu, Z., 2004. Application of
electrospray ionization mass spectrometry in rapid typing offengycin
homologues
produced by Bacillus subtilis. Letters Appl. Microbiol. 39, 98-102.
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
BUDAPEST TRDA i Y ON THE E" i'FILNM ZONAL
RECOGNITION OIi'HF 171 ['O`;[TOI M[CROORUANISMS
FOR THE Ff1RPO5ES OF FA'FEN d PROCEDURE oPõtscue
~anmiane vor,
Mikrao.ganlsmer.
y el ZefE'aUEÃ c, en 3mbt 3
[MIr RNATIONA1, FORM
h4areopolo Fngineerfng S.p.A.
Via XI Settemlire, 37
12011 l_ior'go 5, f?alrnazzo ((:N) REC73P'P (N THE CASK OF AN
OR[O1NALDI;PPORIT
ssued pursuant to Rote 7.I by Ibc
Italy !NTI:RNATIONAT,F)F,I'OI;ITART AIETEORl"I'V
deaLiticd at the bottcnt of this page
1. IDGN'rEFICATION OF1'ON MICROORGANISM
Idenrifioafion reference given by Ito DRPOS'EOR: Acrcosion number given by the
fN'1`ERNATLONAI. DEYOSIT'.ARY A1.rIHUR7TY:
Vs7T111
175M 21035
II. SC[LNTINIC I)ESCILIPTION AND/OR PROPOSM TARUOOMIeL)RSIGNATIO,N
Ttrc micrao,~anian idoutifiod 11ok: I. above won accompanied by;
ascEentifadescription
(R } , propened LaxrntoiniP desigar[LUOn
i Mark 'with a cross wlscro :tppii enble).
In. RECEIPT AND ACCEPTANCE
------------------
This hiicer7atinnal IJepnskaryAulhoriLyaceopls titeEltieCUo1'r+8ainna i/o
dRrorl under L xho>'e, which woneo oio it by ilo' 2008-0I- 10
(Datevi'thea gin 01deltc~it}'_ .
1V. RECEIPT Of REQUEST FOR CONV1ERSION
The microorganism identified under 1 above coos ,)~dewed by ittis (ii r
ationai 7cpos lacy Authority e nt (due of original depoaitl
^nd s rot1m si: l<r aonvoet the n: ighlal depesil to a deposit nook( the. Buhl-
;To Tosny moo Deceived by it os (date of ree aipt of rclinest
for cenlers[on).
V. aENTERNAFIQHAL DFPL51 IART AUTI IORrrS'
Name, f)SMI UEurSC1[r SAMMLUNO VON Sigool ur(a) ofprr~sem(s} having the power
to roprcaout the
EVLIKROORGANISMR?I U'h7D ZELLKULTUREN Gull Depositaty Aullicoity r,r
afanthoiiml of)+ciat(sj:
Address. [uhoffeestr. 7 11
D-3,8124 [ir;umschueiR /
Date: 20(15-01-15
Whcte. Rule 6.4 (d) applies, such dale is the date on ;vlocli the Polus of
international depotLtary authority was acquired.
Penn DS\4L-8K'4 (no/a p:cgr.) t1R120{i6
CA 02744172 2011-05-18
WO 2010/067245 PCT/IB2009/055334
FBU11A EST TREATY ON TIM IN'TERNATIONM,
AFC V014 T HI; FIIIRPOSES Ol I A PROCEDURE Aft n 1 th' O
Ir;~a ~hrt
Iv!ba,DgnDlt,nDn
or.:E 2ellkutturm GrabN a
IN'i ERNA I'tON.AT. FORM
Marcopolo Engineering S.p.A.
Via X1 SetE.emllre, 37
12011 Bongo S, Dalmazao(CAI)
VIABILITY STATE MENT
Italy ur riud pot to tJ Rule I0 2 by iha
INTERNATIONAL DI iPOS1T AP Y AUTFIO IN PY
4dcnrifocd at doe bottom of Ibis page
I. (E[ OSITO1 ll, IDRNTIPECATION OP TIIR M ICROORU,4!1I5h7
Murcopolo Engineering SpA. Accession nntnber gi vctt by the
Via XI Setteuollre, 37 N"ITUI NA ] ZONAL D1:POSI'IARY A[;THORITY7
Address 12011 Rotgn S. 1)alrnarrn (CN)
I3siu ILI;$
Italy
Date of the deposit ac Ilse iransfcrt
200E 01-10
III VIABILITY SFATIFML=NT
Tire viabitity tr1the utirraoluarlE a idattillsd Under Ei obeut stns tcalasi
Ott 2008_01-1 {3 -
On that dirs. the said mictnorgaai&rn was
( )' la longer viable
IV. CONIXUONS Uy0FIZi WLLICId 1I1L VIAIEILE3'Y TEST HAS BEEN PF.RFORMIF:D'
V iNTFRNATION AI. D.I'iaS}]'ARY AUTHORITY
--- ---------------- ---------
hlnsne: D51¾Zd7EJI SCAR SAMMLUNO Void signature(s) ul'po aou(s] having the
pow[ to wprescltt the.
hIIKRt}UF{0 NISM EN lit l) "ZE1-LKUL'I'U'RLN' fiIrrhN h it t iatitntal
Depositary Authority u3 oCautlturii.:d offiNr Its)':
Addtaoa:. Inltolkenstt. 7 Fl
[]~33124 F7 r nacchweig / ,/y am. / _
Bala- 2008-01-15
IUfllC9te lie data of otpitlal delwtlt nr, wltr ac a now dcllosit tot' teotr0
6 Iota boar IIoa(IC, hit 1n11;t IC -.111 re Eet'.,nt Y}atC (date of tI1n now
depute a]' chili
Of Lhc tt'itliSfo'r1.
In be cases tcfct red to in Rule 10.2(x) (11) and (iii), rafts Irt the mast
recant oinhiliry taut,
04ark with a crass the applicahia box.
' Fill Su if the nfonatatiau I'm ken tcgoestui mind if the rcaelts of the trot
wee uepative.
Form IISMZ-131111) (s)le page) 0&2006
